3,5-二氢-5-甲基-N-3-吡啶基苯并[1,2-b：4,5-b']二吡咯-1(2H)-羧酰胺盐酸盐 | 1197334-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3,5-二氢-5-甲基-N-3-吡啶基苯并[1,2-b：4,5-b']二吡咯-1(2H)-羧酰胺盐酸盐
• 英文名称: SB 206553 hydrochloride
• 英文别名: 1-methyl-N-pyridin-3-yl-6,7-dihydropyrrolo[2,3-f]indole-5-carboxamide;hydrochloride
• CAS: 1197334-04-5
• 化学式: C17H17ClN4O
• 分子量: 328.8
• InChiKey: VGEMBOFBPSNOIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.59
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  50.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
  申请人：Chen Chien-Hung

  公开号：US20120183600A1

  公开（公告）日：2012-07-19

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
• PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF
  申请人：ALS MOUNTAIN LLC

  公开号：US20140350064A1

  公开（公告）日：2014-11-27

  The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.
• SEROTONIN 2C RECEPTOR ANTAGONISTS TO PREVENT AND TREAT STRESS-RELATED TRAUMA DISORDERS
  申请人：Massachusetts Institute of Technology

  公开号：US20170007618A1

  公开（公告）日：2017-01-12

  The invention relates to methods for preventing stress-associated disorders. These disorders may be treated with a serotonin 2c receptor (5-HT2CR) antagonist prior to, during, or following a stress-related event. Stress-associated disorders include, for instance, post-traumatic stress disorder (PTSD).
• COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY
  申请人：ZOGENIX INTERNATIONAL LIMITED

  公开号：US20170071949A1

  公开（公告）日：2017-03-16

  Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.
• [EN] SEROTONIN 2C RECEPTOR ANTAGONISTS TO PREVENT AND TREAT STRESS-RELATED TRAUMA DISORDERS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR 2C DE LA SÉROTONINE POUR PRÉVENIR ET TRAITER LES LÉSIONS TRAUMATIQUES LIÉES AU STRESS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2016205631A1

  公开（公告）日：2016-12-22

  The invention relates to methods for preventing stress-associated disorders. These disorders may be treated with a serotonin 2c receptor (5-HT2CR) antagonist prior to, during, or following a stress-related event. Stress-associated disorders include, for instance, post-traumatic stress disorder (PTSD).